You just read:

EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1/2a Clinical Study of Targeted Cytotoxic Immunotherapy

News provided by

EnGeneIC Limited

May 09, 2019, 17:05 ET